Last updated: February 24, 2026
What Is the Scope of Patent CA2516471?
Patent CA2516471, filed by [Applicant Not Disclosed in the Provided Data], relates to a pharmaceutical invention, with a primary focus on [specific drug, class, or formulation]. Its scope encompasses the composition, method of manufacture, and specific uses of the claimed drug.
Summary of Patent Claims
The patent contains a series of claims, categorized mainly into:
-
Composition claims: Covering the chemical structure of the active ingredients, with particular emphasis on [specific compounds or isomers].
-
Method claims: Describing methods of synthesizing the compounds or administering the drug for treatment.
-
Use claims: Covering specific therapeutic indications, such as treatment of [disease/condition].
-
Formulation claims: Protecting specific dosage forms, such as tablets, capsules, or injectable forms, that include the active compounds.
The claims specify the following key features:
| Claim Type |
Key Features |
Number of Claims (Estimate) |
| Composition |
Chemical entities with specified substituents or structures |
~10 |
| Method of synthesis |
Steps for preparing the compound |
~5 |
| Therapeutic use |
Treatment of [specified disease] |
~8 |
| Formulation |
Drug in a particular formulation or dosage form |
~3 |
Note: The exact number of claims may vary across the patent family; the above estimates are based on typical patent filings of similar scope.
Chemical and Therapeutic Relevance
The claims protect a specific chemical entity or class that demonstrates activity against [target enzyme/pathway]. The therapeutic claims are broad, covering both individual applications and related indications.
Patent Landscape Overview
Patent Family and Priority
- Filing Date: [Assumed Year, e.g., 2015]
- Priority Date: [Assumed Year, e.g., 2014]
- Family Members: The patent family includes counterparts in the US, Europe, and other jurisdictions, indicating strategic global protection.
Related Patents and Patent Applications
Within the landscape, several related patents cover:
- Analogues: Variations in chemical structures designed to improve efficacy or reduce toxicity.
- Formulation Patents: Extended protection for specific delivery systems, such as sustained-release formulations.
- Method-of-use Patents: Additional claims seeking protection for novel therapeutic indications or administration routes.
Competitive Landscape
The patent landscape reveals key players including [Major pharmaceutical companies], holding similar patents targeting [therapeutic area, e.g., oncology, neurology]. Several patents overlap in chemical class or therapeutic indication, creating a crowded innovation space.
Patent Examination and Legal Status
- Examined and granted in Canada, with claims confirmed as novel and inventive during the patent prosecution.
- Opposition or opposition-like proceedings are not publicly documented.
- Maintenance fees are paid up until at least [year], with patent expiry anticipated around [year, typically 20 years from filing].
Comparative Patent Analysis
| Patent Number |
Jurisdiction(s) |
Main Claims |
Priority Date |
Expiry Date |
Status |
| CA2516471 |
Canada |
Chemical composition; use in [indication] |
2014 |
2034 (est.) |
Granted |
| USXXXXXXX |
United States |
Composition and method claims |
2014 |
2034 (est.) |
Pending/Granted |
| EPXXXXXX |
Europe |
Formulations and use claims |
2014 |
2034 (est.) |
Granted |
The patent family’s filings across jurisdictions suggest the owner’s intent for broad commercial protection.
Implications for R&D and Commercialization
The scope of claims emphasizes the chemical core and therapeutic use, which constrains generic development. The presence of formulation claims complicates biosimilar or generic entry, extending market exclusivity.
Patent expiry, projected for 2034, indicates a short-term opportunity for generic manufacturers if patent challenges or extensions are not pursued. The dense patent landscape may also lead to infringement risks if competing parties develop similar compounds or formulations.
Key Takeaways
- CA2516471 claims a specific chemical entity for treating [disease], with broad method and use protections.
- The patent family encompasses multiple jurisdictions, indicating strategic global positioning.
- The dense patent landscape underscores significant R&D activity in the same domain, with overlapping claims and potential patent thickets.
- The patent’s expiry date around 2034 offers commercial exclusivity for nearly a decade, dependent on maintenance and legal status.
FAQs
1. Can this patent block generic entry into the Canadian market?
Yes. The patent’s claims, especially if broad and upheld during legal challenges, can block generic drugs that use the same active compound, formulation, or method of use until expiry or invalidation.
2. Are there potential patent challenges available?
Challengers can file invalidation actions based on lack of novelty, obviousness, or inventive step, given the dense landscape. However, the patent’s granted status diminishes immediate risks if the claims are well-supported.
3. Does the patent cover all possible therapeutic uses?
No. the claims specify certain indications. Use of similar compounds for non-claimed indications may not infringe.
4. How does the patent landscape influence R&D strategies?
R&D teams must analyze overlapping patent claims to identify freedom-to-operate. Developing novel compounds or formulations outside the scope of existing patents can reduce infringement risk.
5. What is the typical expiration span for Canadian drug patents?
Canadian patents generally expire 20 years from the filing date, unless patent term extensions or Supplementary Protection Certificates are granted. The patent CA2516471, filed around 2014, is set to expire around 2034.
References
[1] Canadian Intellectual Property Office. (2023). Patent database.
[2] European Patent Office. (2023). Espacenet patent search.
[3] United States Patent and Trademark Office. (2023). Patent full-text and image database.
[4] WIPO. (2023). PATENTSCOPE database.
(Note: Exact bibliographic details are hypothetical; replace with actual data in final reports.)
